NCT05170334

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

A Phase II Study of Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.

Conditions

• Metastatic Uveal Melanoma

Interventions

Type	Name	Description
DRUG	Binimetinib	Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
DRUG	Belinostat	Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles

Timeline

• Start date: 2021-12-15
• Primary completion: 2025-12-01
• Completion: 2028-01-01
• First posted: 2021-12-27
• Last updated: 2026-04-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study